Strategy of Laboratory Medicine – EFLM VisionMario Plebanion December 29, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 30. doi: 10.1515/cclm-2025-1678. Online ahead of print. ABSTRACT The strategic direction of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) is guided by global healthcare trends, rapid technological advancements, and the evolving role of laboratory professionals in modern medicine. The aim is to position laboratory medicine as … Read more

Kappa Index predicts disease activity and transition to high-efficacy therapies in multiple sclerosisSimone Marchesellion December 27, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 29. doi: 10.1515/cclm-2025-1339. Online ahead of print. ABSTRACT OBJECTIVES: The Kappa Index has proven its diagnostic value for multiple sclerosis (MS), while its prognostic potential remains to be fully explored. The objective of this study is thus to investigate the value of the Kappa Index at disease onset in … Read more

From automation to agentic artificial intelligence in laboratory medicine: an opinion of the IFCC Division on Emerging TechnologiesDamien Grusonon December 27, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 29. doi: 10.1515/cclm-2025-1314. Online ahead of print. ABSTRACT Agentic artificial intelligence (AI) systems are distinguished by their ability to invoke multiple tools, compose command chains, and combine chain-of-thought reasoning with deep research to execute complex tasks and take actions. This represents a major evolution beyond machine learning and large … Read more

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemseon December 26, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 29. doi: 10.1515/cclm-2025-1480. Online ahead of print. ABSTRACT OBJECTIVES: Compare Elecsys (Roche) and Simoa (Quanterix) immunoassays for serum glial fibrillary acidic protein (GFAP) using our reference database and Z scores, and evaluate their prognostic value for progression independent of relapse activity (PIRA) in multiple sclerosis (MS). METHODS: Platform correlation … Read more

Analytical verification and comparative assessment of the new Atellica IM high-sensitivity prostate specific antigen assayXavier Filellaon December 22, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 23. doi: 10.1515/cclm-2025-1431. Online ahead of print. ABSTRACT OBJECTIVES: Despite standardization efforts, significant inter-assay variability persists among prostate-specific antigen (PSA) tests, impacting prostate cancer (PCa) diagnosis and monitoring. We aimed to evaluate the analytical and clinical performance of the newly developed Atellica IM high-sensitivity PSA (hsPSA Atellica) assay compared … Read more

Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patientsJustina Dargvainieneon December 17, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 18. doi: 10.1515/cclm-2025-1476. Online ahead of print. ABSTRACT OBJECTIVES: Neurofilament light chain (NfL) is a biomarker of neuroaxonal damage in various neurological conditions, including multiple sclerosis (MS). With new analytical platforms entering the market, standardization of serum NfL (sNfL) measurement is essential. This study compared sNfL levels across three … Read more

Development and validation of a candidate reference measurement procedure for free triiodothyronine and free thyroxine in human serum using equilibrium dialysis isotope-dilution liquid chromatography-tandem mass spectrometryMin Zhanon December 17, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 18. doi: 10.1515/cclm-2025-0874. Online ahead of print. ABSTRACT OBJECTIVES: Free triiodothyronine (FT3) and free thyroxine (FT4) are important diagnostic markers for assessing thyroid function. However, their accurate quantification remains challenging due to low serum concentrations. Significant variability exists among current assay methods for measuring FT3 and FT4. This study … Read more

Serial measurements of neuron specific enolase, glial fibrillary acidic protein and neurofilament light for mortality prediction in patients with severe acute brain injury in the ICUWolmet E Haksteenon December 16, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 17. doi: 10.1515/cclm-2025-1315. Online ahead of print. ABSTRACT OBJECTIVES: Prognostication in patients with severe acute brain injury (SABI) in the Intensive Care Unit (ICU) is complex, often requiring early decisions on life-sustaining therapy. Serum biomarkers such as neurofilament light (NFL), glial fibrillary acidic protein (GFAP) and neuron specific enolase … Read more

Artificial intelligence and machine learning in thrombosis and hemostasis: a scoping review of clinical and laboratory applications, challenges, and future directionsMohammad A Altememion December 16, 2025 at 11:00 am

Clin Chem Lab Med. 2025 Dec 17. doi: 10.1515/cclm-2025-1450. Online ahead of print. ABSTRACT This scoping review followed the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines to systematically map the current landscape of artificial intelligence (AI) and machine learning (ML) applications in the field of thrombosis and hemostasis … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520